Agios Pharmaceuticals Reports the Results for Pyrukynd (mitapivat) in P-III Trial to Treat of Non-Transfusion-Dependent Alpha- or Beta-Thalassemia
Shots:
- The P-III (ENERGIZE) trial evaluates the safety, tolerability & efficacy of Pyrukynd (100mg, BID) vs PBO in patients (n=194) with non-transfusion-dependent (NTD) alpha-/beta-thalassemia for 24wks.
- As per the results, the study met its 1EP of hemoglobin response with an increase of ≥1 g/dL in average hemoglobin concentrations from wk12 to wk24 vs baseline. Moreover, 42.3% vs 1.6% of patients achieved a hemoglobin response
- The study also depicted statistically significant improvement in the 2EPs through a change from baseline in average FACIT-Fatigue subscale score average hemoglobin concentration from wk12 to wk24. Additonally, the company expects to initiate a P-III (ENERGIZE-T) trial for Pyrukynd in TD alpha-/beta-thalassemia
Ref: Agios | Image: Agios
Related News:- Agios’ Pyrukynd (mitapivat) Receives the EC’s Marketing Authorization for the Treatment of Pyruvate Kinase (PK) Deficiency
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.
